CFTR, SAL3, and TWIST1 have been recently shown to be useful for monitoring bladder cancer in a real clinical scenario, as a sensitivity of 96% was achieved by pyrosequencing in combination with urine cytology—however with low specificity (40%) [35]. This evidence concerns the gene TWIST1 and urinary bladder carcinoma.